S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
OTCMKTS:TRUMY

Terumo (TRUMY) Stock Price, News & Analysis

$37.36
+0.45 (+1.22%)
(As of 03/27/2024 ET)
Today's Range
$36.73
$38.09
50-Day Range
$33.43
$39.67
52-Week Range
$25.11
$41.19
Volume
29,362 shs
Average Volume
33,677 shs
Market Capitalization
$27.93 billion
P/E Ratio
39.32
Dividend Yield
0.59%
Price Target
N/A
TRUMY stock logo

About Terumo Stock (OTCMKTS:TRUMY)

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.

TRUMY Stock Price History

TRUMY Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Improved Revenue Growth Is Terumo's Next Major Target
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Lakewood Company Putting People at Risk?
Ivanka Trump
Trump Reinstated To Facebook And Instagram
OMG. Trump Has Started Texting.
See More Headlines
Receive TRUMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terumo and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/28/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical & hospital equipment
Sub-Industry
N/A
Current Symbol
OTCMKTS:TRUMY
Previous Symbol
NASDAQ:TRUMY
Employees
30,207
Year Founded
1964

Profitability

Net Income
$661.01 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.07 billion
Cash Flow
$1.62 per share
Book Value
$11.00 per share

Miscellaneous

Free Float
N/A
Market Cap
$27.93 billion
Optionable
Not Optionable
Beta
0.65

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Shinjiro Sato (Age 64)
    President, CEO, Group Managing Executive Officer & Director
    Comp: $825.21k
  • Mr. Naoki Muto
    Chief Accounting & Financial Officer and Group Executive Officer
  • Itaru Sakaguchi
    Senior Executive Officer & COO
  • Fumihisa Hirose
    Group Managing Executive Officer, GM of Strategic Planning Department & CTO
  • Mr. Shoji Hatano (Age 65)
    Group Senior Mng. Exe. Off. of Corporate Affairs Dept., Legal and Compliance Dept. & Director
  • Ms. Miho Mizuguchi
    Executive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department
  • Tomoko Adachi
    Chief Human Resources Officer & Group Executive Officer
  • James Rushworth
    Group Executive Officer & Chief Commercial Officer
  • Mr. Hikaru Samejima (Age 60)
    Group Senior Managing Executive & Director
  • Mr. Kazunori Hirose (Age 60)
    Group Managing Executive Officer, Chief Manufacturing Officer & Director

Should I Buy Terumo Stock? TRUMY Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Terumo was last updated on Monday, March 25, 2024 at 10:58 AM.

Pros

Here are some ways that investors could benefit from investing in Terumo Co.:

  • Terumo India launches drug-eluting stent, Ultimaster Nagomi, showcasing innovation and product development in the company's portfolio.
  • Terumo Corporation operates in multiple segments, including Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies, providing diversification and revenue streams.
  • Recent launch of new medical products and equipment indicates a commitment to staying competitive and meeting market demands.
  • Strong presence in Japan, Europe, China, the United States, and Asia offers geographical diversification and exposure to various healthcare markets.
  • Current stock price of Terumo Co. reflects positive market sentiment and potential growth opportunities.

Cons

Investors should be bearish about investing in Terumo Co. for these reasons:

  • The medical & hospital equipment industry can be highly competitive, leading to pricing pressures and potential margin squeezes.
  • Regulatory challenges in different regions could impact product approvals and market access, affecting revenue streams.
  • Global economic uncertainties may impact healthcare spending, potentially affecting demand for Terumo's products.
  • Dependency on successful product launches and innovations for sustained growth, which can pose risks in a rapidly evolving industry.
  • Fluctuations in currency exchange rates could impact international sales and profitability.

TRUMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Terumo stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Terumo in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TRUMY shares.
View TRUMY analyst ratings
or view top-rated stocks.

How have TRUMY shares performed in 2024?

Terumo's stock was trading at $32.62 at the beginning of 2024. Since then, TRUMY stock has increased by 14.5% and is now trading at $37.3550.
View the best growth stocks for 2024 here
.

Are investors shorting Terumo?

Terumo saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 700 shares, a drop of 76.7% from the February 29th total of 3,000 shares. Based on an average trading volume of 27,800 shares, the days-to-cover ratio is currently 0.0 days.
View Terumo's Short Interest
.

How were Terumo's earnings last quarter?

Terumo Co. (OTCMKTS:TRUMY) posted its quarterly earnings results on Wednesday, February, 7th. The company reported $0.27 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.27. The company earned $1.62 billion during the quarter. Terumo had a net margin of 11.14% and a trailing twelve-month return on equity of 8.26%.

Is Terumo a good dividend stock?

Terumo (OTCMKTS:TRUMY) pays an annual dividend of $0.22 per share and currently has a dividend yield of 0.59%. The dividend payout ratio is 23.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TRUMY will have a dividend payout ratio of 16.54% next year. This indicates that the company will be able to sustain or increase its dividend.

When did Terumo's stock split?

Shares of Terumo split before market open on Thursday, March 28th 2024. The 2-1 split was announced on Thursday, March 28th 2024. The newly minted shares will be distributed to shareholders after the closing bell on Thursday, March 28th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How do I buy shares of Terumo?

Shares of TRUMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:TRUMY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners